Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 113 clinical trials
The Canadian Glomerulonephritis Registry and Translational Research Initiative (CGNR)

Glomerulonephritis (GN) is one of the most important causes of kidney failure in Canada. These comprise a group of "rare" diseases (<5 per 250,000 population), yet GN is a leading cause of kidney failure and accounts annually for close to 20% of incident cases of end stage kidney disease (ESKD) …

focal segmental glomerulosclerosis
mpgn
nephropathy
anca
kidney biopsy
  • 11 views
  • 27 Feb, 2022
  • 1 location
Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort

Lupus nephritis (LN) is one of the main manifestationsin SLE patients, having an important impact on morbidity and mortality. Renal biopsy is the "gold standard" for the diagnosis of LN, however

calcineurin inhibitors
systemic lupus erythematosus
nephritis
anti-dna antibodies
  • 7 views
  • 07 May, 2021
  • 1 location
Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus (JD001)

The aim of this research project is to better understand the origin and clinical significance of two lupus-specific "genetic signatures" (IFN signature and plasma cell signature) in patient subgroups with well-defined clinical characteristics. Our aim is to correlate these genetic signatures with cell activation profiles and the production of specific …

systemic lupus erythematosus
  • 0 views
  • 21 Jul, 2022
  • 1 location
LUPKYNIS US Registry Trial

This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).

nephritis
  • 0 views
  • 19 Jun, 2022
  • 1 location
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population

This is an open-label, prospective, single-arm, observational study in patients with Lupus nephritis (LN) who newly (i.e.,for the first time) received treatment of Enteric-coated Mycophenolate

mycophenolate
cellular casts
nephritis
histological diagnosis
proteinuria
  • 0 views
  • 22 Sep, 2022
  • 4 locations
Precision Medicine in LN: A Multicenter Proof-of-concept Study for Histopathological Biomarkers Analysis in Renal Biopsy

Lupus nephritis (LN) may affect approximately half of patients with Systemic Lupus Erythematosus (SLE). LN is a major cause of morbidity and the most important predictor of mortality in patients

cyclophosphamide
treatment regimen
mycophenolate
lupus
rituximab
  • 0 views
  • 11 May, 2022
  • 1 location
European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

The hereditary type IV collagen disease Alport syndrome inevitably leads to end-stage renal disease. Currently there are no therapies known to improve outcome. Our non-interventional, observational study investigates, if medications such as ACE-inhibitors can (1) delay time to dialysis and (2) improve life-expectancy within three generations of Alport-families in Europe.

Accepts healthy volunteers
  • 433 views
  • 05 Jun, 2022
  • 1 location
Value of Uric Acid as Early Predictor of Lupus Nephritis

The aim of the present work is to determine the role of uric acid as a predictor and prognostic factor in the development of lupus nephritis.

  • 0 views
  • 17 Jun, 2022
  • 1 location
Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis

This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf

nephritis
lupus
  • 0 views
  • 13 May, 2022
  • 1 location
Nephrotic Syndrome Study Network (NEPTUNE)

Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of …

immunosuppression
focal segmental glomerulosclerosis
minimal change disease
edema
end stage renal disease
  • 363 views
  • 21 Mar, 2022
  • 35 locations